A preliminary evaluation of the safety and tolerance of medicinally ingested vinegar in individuals with type 2 diabetes

Carol Johnston, Andrea M. White, Shannon M. Kent

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Vinegar (VIN) ingestion at mealtime reduces postprandial glycemia and may benefit individuals with diabetes; hence, the medicinal use of VIN has increased in recent years. This study examined the safety and tolerance of medicinally ingested VIN in type 2 diabetics. Participants (n = 27) were stratified by gender, age, and body mass and randomized into three groups: commercial VIN pills (the reference treatment [REF] (30 mg of acetic acid daily), pickles (PCK) (∼1,400 mg of acetic acid daily), or VIN (2,800 mg of acetic acid daily). Participants continued their normal eating habits during the 12-week trial. At baseline and weeks 6 and 12, fasting blood and urine samples were collected, and adverse changes in bowel movements, frequency of burping or flatulence, and episodes of acid reflux were recorded. Reporting frequency for adverse events did not vary significantly by group during the trial; however, 50-56% of PCK and VIN participants reported at least one treatment-emergent adverse event at week 6 as compared to 11% of REF participants (P = .110). Urinary pH was significantly reduced in VIN participants at week 12 as compared to the other groups (-9% vs. +3% and +2% for the PCK and REF groups, respectively, P = .023). At week 6 there was a tendency for aspartate aminotransferase concentrations to increase in the VIN group as compared to the other groups (+17% vs. +8% and -8% for VIN, PCK, and REF, respectively; P = .090). These data indicate that chronic VIN ingestion may influence hepatic function and metabolic pathways aside from glucose metabolism.

Original languageEnglish (US)
Pages (from-to)179-183
Number of pages5
JournalJournal of Medicinal Food
Volume11
Issue number1
DOIs
StatePublished - Mar 1 2008

Fingerprint

vinegars
noninsulin-dependent diabetes mellitus
Acetic Acid
Type 2 Diabetes Mellitus
Safety
pickles
acetic acid
ingestion
flatulence
Eating
liver function
Flatulence
eating habits
aspartate transaminase
blood glucose
fasting
diabetes
biochemical pathways
Feeding Behavior
urine

Keywords

  • Acetic acid
  • Aminotransferases
  • Diabetes
  • Pickles
  • Urinary pH

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

A preliminary evaluation of the safety and tolerance of medicinally ingested vinegar in individuals with type 2 diabetes. / Johnston, Carol; White, Andrea M.; Kent, Shannon M.

In: Journal of Medicinal Food, Vol. 11, No. 1, 01.03.2008, p. 179-183.

Research output: Contribution to journalArticle

@article{4b7f3db171754da9b74185f18cbdb652,
title = "A preliminary evaluation of the safety and tolerance of medicinally ingested vinegar in individuals with type 2 diabetes",
abstract = "Vinegar (VIN) ingestion at mealtime reduces postprandial glycemia and may benefit individuals with diabetes; hence, the medicinal use of VIN has increased in recent years. This study examined the safety and tolerance of medicinally ingested VIN in type 2 diabetics. Participants (n = 27) were stratified by gender, age, and body mass and randomized into three groups: commercial VIN pills (the reference treatment [REF] (30 mg of acetic acid daily), pickles (PCK) (∼1,400 mg of acetic acid daily), or VIN (2,800 mg of acetic acid daily). Participants continued their normal eating habits during the 12-week trial. At baseline and weeks 6 and 12, fasting blood and urine samples were collected, and adverse changes in bowel movements, frequency of burping or flatulence, and episodes of acid reflux were recorded. Reporting frequency for adverse events did not vary significantly by group during the trial; however, 50-56{\%} of PCK and VIN participants reported at least one treatment-emergent adverse event at week 6 as compared to 11{\%} of REF participants (P = .110). Urinary pH was significantly reduced in VIN participants at week 12 as compared to the other groups (-9{\%} vs. +3{\%} and +2{\%} for the PCK and REF groups, respectively, P = .023). At week 6 there was a tendency for aspartate aminotransferase concentrations to increase in the VIN group as compared to the other groups (+17{\%} vs. +8{\%} and -8{\%} for VIN, PCK, and REF, respectively; P = .090). These data indicate that chronic VIN ingestion may influence hepatic function and metabolic pathways aside from glucose metabolism.",
keywords = "Acetic acid, Aminotransferases, Diabetes, Pickles, Urinary pH",
author = "Carol Johnston and White, {Andrea M.} and Kent, {Shannon M.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1089/jmf.2007.574",
language = "English (US)",
volume = "11",
pages = "179--183",
journal = "Journal of Medicinal Food",
issn = "1096-620X",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - A preliminary evaluation of the safety and tolerance of medicinally ingested vinegar in individuals with type 2 diabetes

AU - Johnston, Carol

AU - White, Andrea M.

AU - Kent, Shannon M.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Vinegar (VIN) ingestion at mealtime reduces postprandial glycemia and may benefit individuals with diabetes; hence, the medicinal use of VIN has increased in recent years. This study examined the safety and tolerance of medicinally ingested VIN in type 2 diabetics. Participants (n = 27) were stratified by gender, age, and body mass and randomized into three groups: commercial VIN pills (the reference treatment [REF] (30 mg of acetic acid daily), pickles (PCK) (∼1,400 mg of acetic acid daily), or VIN (2,800 mg of acetic acid daily). Participants continued their normal eating habits during the 12-week trial. At baseline and weeks 6 and 12, fasting blood and urine samples were collected, and adverse changes in bowel movements, frequency of burping or flatulence, and episodes of acid reflux were recorded. Reporting frequency for adverse events did not vary significantly by group during the trial; however, 50-56% of PCK and VIN participants reported at least one treatment-emergent adverse event at week 6 as compared to 11% of REF participants (P = .110). Urinary pH was significantly reduced in VIN participants at week 12 as compared to the other groups (-9% vs. +3% and +2% for the PCK and REF groups, respectively, P = .023). At week 6 there was a tendency for aspartate aminotransferase concentrations to increase in the VIN group as compared to the other groups (+17% vs. +8% and -8% for VIN, PCK, and REF, respectively; P = .090). These data indicate that chronic VIN ingestion may influence hepatic function and metabolic pathways aside from glucose metabolism.

AB - Vinegar (VIN) ingestion at mealtime reduces postprandial glycemia and may benefit individuals with diabetes; hence, the medicinal use of VIN has increased in recent years. This study examined the safety and tolerance of medicinally ingested VIN in type 2 diabetics. Participants (n = 27) were stratified by gender, age, and body mass and randomized into three groups: commercial VIN pills (the reference treatment [REF] (30 mg of acetic acid daily), pickles (PCK) (∼1,400 mg of acetic acid daily), or VIN (2,800 mg of acetic acid daily). Participants continued their normal eating habits during the 12-week trial. At baseline and weeks 6 and 12, fasting blood and urine samples were collected, and adverse changes in bowel movements, frequency of burping or flatulence, and episodes of acid reflux were recorded. Reporting frequency for adverse events did not vary significantly by group during the trial; however, 50-56% of PCK and VIN participants reported at least one treatment-emergent adverse event at week 6 as compared to 11% of REF participants (P = .110). Urinary pH was significantly reduced in VIN participants at week 12 as compared to the other groups (-9% vs. +3% and +2% for the PCK and REF groups, respectively, P = .023). At week 6 there was a tendency for aspartate aminotransferase concentrations to increase in the VIN group as compared to the other groups (+17% vs. +8% and -8% for VIN, PCK, and REF, respectively; P = .090). These data indicate that chronic VIN ingestion may influence hepatic function and metabolic pathways aside from glucose metabolism.

KW - Acetic acid

KW - Aminotransferases

KW - Diabetes

KW - Pickles

KW - Urinary pH

UR - http://www.scopus.com/inward/record.url?scp=41349119901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349119901&partnerID=8YFLogxK

U2 - 10.1089/jmf.2007.574

DO - 10.1089/jmf.2007.574

M3 - Article

C2 - 18361754

AN - SCOPUS:41349119901

VL - 11

SP - 179

EP - 183

JO - Journal of Medicinal Food

JF - Journal of Medicinal Food

SN - 1096-620X

IS - 1

ER -